Home > Haematology > ASH 2021 > Chronic Leukaemia > Investigational therapies superior to standard-of-care in double-exposed CLL

Investigational therapies superior to standard-of-care in double-exposed CLL

Presented By
Dr Meghan Thompson, Memorial Sloan Cancer Center, NY, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASH 2021
Patients with chronic lymphocytic leukaemia (CLL) with prior exposure to both a covalent Bruton’s tyrosine kinase (BTK) inhibitor and venetoclax demonstrated better responses to non-covalent BTK inhibitors, allogeneic stem cell transplantation (SCT), or CAR T-cell therapy than to PI3K inhibitors or chemo+/-immunotherapy (CIT). These results cast doubt on the use of PI3K inhibitors or CIT in double-exposed patients with CLL [1]. A subset of patients with CLL treated with both a covalent BTK inhibitor and venetoclax will still develop progressive disease. Dr Meghan Thompson (Memorial Sloan Cancer Center, NY, USA) explained that data is limited regarding therapy efficacy in these double-exposed patients. Therefore, practice patterns vary. The current international, retrospective, multicentre study compared the efficacy of in USA available approved options (i.e. CIT or PI3K inhibitors) with investigational options (i.e. non-covalent BTK inhibitors, CAR ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on